YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats

European Journal of Pharmacology

Volumn 458, Issue 1-2, 2003, Pages 183-189

  Hsieh, Gin C ^a   O'Neill, Alyssa B ^a   Moreland, Robert B ^a   Sullivan, James P ^a   Brioni, Jorge D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Apomorphine; Corpus cavernosum; Guanylate cyclase; Nitric oxide (NO); Penile erection; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; APOMORPHINE; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; GUANYLATE CYCLASE INHIBITOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; SILDENAFIL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOSE CALCULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MALE; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE RELAXATION;

ANIMALS; CELLS, CULTURED; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; GUANYLATE CYCLASE; INDAZOLES; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NITRIC OXIDE; NITROPRUSSIDE; OXADIAZOLES; PENILE ERECTION; PENIS; PHENYLEPHRINE; QUINOXALINES; RABBITS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0037223315     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02730-9     Document Type: Article

References (33)

1. Andersson K.-E. Pharmacology of penile erection. Pharmacol. Rev. 53:2001;417-450.
2. Andersson K.-E., Wagner G. Physiology of erection. Physiol. Rev. 175:1995;191-236.
3. Artz J.D., Toader V., Zavorin S.I., Bennett B.M., Thatcher G.R. In vitro activation of soluble guanylyl cyclase and nitric oxide release: a comparison of no donors and no mimetics. Biochemistry. 40:2001;9256-9264.
4. Behrends S., Steenpass A., Porst H., Scholz H. Expression of nitric oxide-sensitive guanylyl cyclase subunits in human corpus cavernosum. Biochem. Pharmacol. 59:2000;713-717.
5. Brioni J.D., Nakane M., Hsieh G.C., Moreland R.B., Kolasa T., Sullivan J.P. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int. J. Impot. Res. 14:2002;8-14.
6. Carvajal J.A., Germain A.M., Huidobro-Toro J.P., Weiner C.P. Molecular mechanism of cyclic GMP-mediated smooth muscle relaxation. J. Cell. Physiol. 184:2000;409-420.
7. Denninger J.W., Marletta M.A. Guanylate cyclase and the NO/cyclic GMP signaling pathway. Biochim. Biophys. Acta. 1411:1999;334-350.
8. Friebe A., Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 53:1998;123-127.
9. Galle J., Zabel U., Hübner U., Hatzelmann A., Wagner B., Wanner C., Schmidt H.H.H.W. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. 127:1999;195-203.
10. Garthwaite J., Boulton C.L. Nitric oxide signalling in the central nervous system. Annu. Rev. Physiol. 57:1995;683-706.
11. Giuliano F., Allard J. Dopamine and sexual function. Int. J. Impot. Res. 13:2001;S18-S28.
12. Heaton J. Apomorphine: an update of clinical trial results. Int. J. Impot. Res. 12:2000;S67-S73.
13. Hobbs A.J. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol. Sci. 18:1997;484-491.
14. Hsieh G.C., Kolasa T., Sullivan J.P., Brioni J.D. Dual mechanism of action of nicorandil on rabbit corpus cavernosal smooth muscle tone. Int. J. Impot. Res. 13:2001;240-246.
15. Hsieh G.C., O'Neill A.B., Pong M.P., Chang R., Seifert T.R., Sullivan J.P., Brioni J.D. Apomorphine as a pharmacological tool for studying penile erection mediated by dopaminergic receptors. Soc. Neurosci. Abstr. 2:2001;958.17.
16. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood. 84:1994;426-433.
17. Krukoff T.L. Central actions of nitric oxide in regulation of autonomic function. Brain Res., Brain Res. Rev. 30:1999;52-65.
18. Lee Y.C., Martin E., Murad F. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10763-10768.
19. Liu S.P., Guh J.H., Teng C.M., Lai M.K., Hsieh J.T. YC-1, a NO-independent soluble guanylate cyclase stimulator, relaxes rabbit cavernous smooth muscle via increasing intracellular cyclic GMP. Int. J. Impot. Res. 12:2000;S18. (abstract).
20. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Stewart I., Park J., Schulz S., Chepenik K.P., Waldman S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52:2000;375-414.
21. Melis M.R., Succu S., Argiolas A. Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawning. Eur. J. Neurosci. 8:1996;2056-2063.
22. Mizusawa H., Hedlund P., Brioni J.D., Sullivan J.P., Andersson K.-E. Nitric oxide independent activation of guanylate cyclase by YC-1 cause erectile responses in the rat. J. Urol. 167:2002;2276-2281.
23. Moreland R.B., Hsieh G., Nakane M., Brioni J.D. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J. Pharmacol. Exp. Ther. 296:2001;225-234.
24. Mulsch A., Bauersachs J., Schafer A., Stasch J.P., Kast R., Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 120:1997;681-689.
25. Nakane M., Hsieh G.C., Miller L.N., Chang R., Terranova M.A., Moreland R.B., Kolasa T., Brioni J.D. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int. J. Impot. Res. 14:2002;121-127.
26. O'Reilly D.A., McLaughlin B.E., Marks G.S., Brien J.F., Nakatsu K. YC-1 enhances the responsiveness of tolerant vascular smooth to glyceryl trinitrate. Can. J. Physiol. Pharm. 79:2001;43-48.
27. Sato Y., Christ J.G., Horita H., Adachi H., Suzuki N., Tsukamoto T. The effects of alterations in nitric oxide levels in the paraventricular nucleus on copulatory behavior and reflexive erections in male rats. J. Urol. 162:1999;2182-2185.
28. Schmidt K., Schrammel A., Koesling D., Mayer B. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. Mol. Pharmacol. 59:2001;220-224.
29. Stone J.R., Marletta M.A. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem. Biol. 5:1998;255-261.
30. Tseng C.M., Tabrizi-Fard M.A., Fung H.L. Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. J. Pharmacol. Exp. Ther. 292:2000;737-742.
31. Wegener J.W., Gath I., Forstermann U., Nawrath H. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br. J. Pharmacol. 122:1997;1523-1529.
32. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 116:1995;1973-1978.
33. Zhao Y., Brandish P., DiValentin M., Schelvis J.P., Babcock G.T., Marletta M.A. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry. 39:2000;10848-10854.